TriangleNCT01777152 · OUTCOME
Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Up to 60 months
What was measured
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
Analysis population: This analysis population includes only patients with systemic anaplastic large cell lymphoma (sALCL).
Groups in this outcome
A+CHP
brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
CHOP
cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
| Group | Source count |
|---|---|
| A+CHP | 162 |
| CHOP | 154 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| A+CHP | 55.66 | Not reported | 15.61 | NA | Insufficient number of participants experienced events |
| CHOP | 32.03 | Not reported | 4.57 | NA | Insufficient number of participants experienced events |
Complete source fields
- classes
- categories
- measurements
- comment
- Insufficient number of participants experienced events
- group Id
- OG000
- lower Limit
- 15.61
- upper Limit
- NA
- value
- 55.66
- comment
- Insufficient number of participants experienced events
- group Id
- OG001
- lower Limit
- 4.57
- upper Limit
- NA
- value
- 32.03
- denoms
- counts
- group Id
- OG000
- value
- 162
- group Id
- OG001
- value
- 154
- units
- Participants
- description
- The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
- dispersion Type
- Inter-Quartile Range
- groups
- description
- brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
- id
- OG000
- title
- A+CHP
- description
- cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
- id
- OG001
- title
- CHOP
- param Type
- MEDIAN
- population Description
- This analysis population includes only patients with systemic anaplastic large cell lymphoma (sALCL).
- reporting Status
- POSTED
- time Frame
- Up to 60 months
- title
- Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice